Candel Therapeutics (CADL) Long-Term Debt Issuances (2022)
Candel Therapeutics (CADL) posted Long-Term Debt Issuances of $19.9 million for Q1 2022.
Candel Therapeutics (CADL) Long-Term Debt Issuances (2022) Analysis & Trends
Candel Therapeutics has reported Long-Term Debt Issuances for 1 years, with the latest figure at $19.9 million in Q1 2022.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $19.9 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $19.9 million (changed N/A YoY) and the FY2025 annual result came in at $47.9 million, changed N/A from the prior year.
- Long-Term Debt Issuances was little changed at $19.9 million in Q1 2022 per CADL's latest filing.
- Over five years, Long-Term Debt Issuances peaked at $19.9 million in Q1 2022 and troughed at $19.9 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 19.91 Mn |
| Mar 31, 2022 | 19.91 Mn |